Relapse of leukemia is the major cause of failure after autologous stem cell transplantation due t o reinfusion of residual clonogenic cells and the absence of an immune-mediated graft-versus-leukemia effect. To provide an antileukemia effect, immune-activating cytokines have been given t o patients after transplantation. Systemic administration of such cytokines early after transplantation is often accompanied by substantial side effects, and it is unknown whether sufficient concentrations reach the sites of residual disease in the marrow. As a method of site-directed immunotherapy provided early after stem cell transplantation, we have tested in a murine model whether (1) marrow can be retrovirally transduced with the tumor necrosis factor a (TNFa) gene, (2) local production of TNFa by marrow cells after transplantation can be achieved, and (3) adverse effects of TNFa occurred. Balb/c mice were treated with 5-fluorouracil and bone marrow (BM) was obtained 4 days later. Whole BM was transduced in the presence of interleukin-3 (IL-31, IL-6, and stem cell factor by coculture with the packaging cell line GP+E-86, producing the cDNA for TNFa. Irradiated (1,300 cGy) syngeneic recipient mice were given IO6 trans-ATIENTS RECEIVING a bone marrow transplant (BMT) from an allogeneic donor for the treatment of acute or chronic leukemia have a significantly lower relapse rate than those receiving an autologous or syngeneic transplant for the same disease.'.' This finding appears to be caused by (1) the infusion of residual clonogenic cells with the marrow3 and (2) the lack of a graft-versus-leukemia (GVL) effect that can eliminate residual malignant cells remaining in the There is evidence that the alloantigen-driven immune response after allogeneic BMT involves the clonal expansion of T lymphocytes that release, among other cytokines, interleukin-2 (IL-2).' This cytokine can stimulate the production of tumor necrosis factor a (TNFa) by monocytes, T lymphocytes and natural killer cells." Although TNFa is suspected to be involved in the pathology of the tissue damage seen in graft-versus-host disease, it is also believed to contribute to the GVL effect.'.'
Relapse of leukemia is the major cause of failure after autologous stem cell transplantation due t o reinfusion of residual clonogenic cells and the absence of an immune-mediated graft-versus-leukemia effect. To provide an antileukemia effect, immune-activating cytokines have been given t o patients after transplantation. Systemic administration of such cytokines early after transplantation is often accompanied by substantial side effects, and it is unknown whether sufficient concentrations reach the sites of residual disease in the marrow. As a method of site-directed immunotherapy provided early after stem cell transplantation, we have tested in a murine model whether (1) marrow can be retrovirally transduced with the tumor necrosis factor a (TNFa) gene, (2) local production of TNFa by marrow cells after transplantation can be achieved, and (3) adverse effects of TNFa occurred. Balb/c mice were treated with 5-fluorouracil and bone marrow (BM) was obtained 4 days later. Whole BM was transduced in the presence of interleukin-3 (IL-31, IL-6, and stem cell factor by coculture with the packaging cell line GP+E-86, producing the cDNA for TNFa. Irradiated (1,300 cGy) syngeneic recipient mice were given IO6 trans-ATIENTS RECEIVING a bone marrow transplant (BMT) from an allogeneic donor for the treatment of acute or chronic leukemia have a significantly lower relapse rate than those receiving an autologous or syngeneic transplant for the same disease.'.' This finding appears to be caused by (1) the infusion of residual clonogenic cells with the marrow3 and (2) the lack of a graft-versus-leukemia (GVL) effect that can eliminate residual malignant cells remaining in the There is evidence that the alloantigen-driven immune response after allogeneic BMT involves the clonal expansion of T lymphocytes that release, among other cytokines, interleukin-2 (IL-2).' This cytokine can stimulate the production of tumor necrosis factor a (TNFa) by monocytes, T lymphocytes and natural killer cells." Although TNFa is suspected to be involved in the pathology of the tissue damage seen in graft-versus-host disease, it is also believed to contribute to the GVL effect.'. ' TNFa has a number of noncytotoxic actions that are re- Despite its documented antitumor effects, TNFa has proven to be unsuitable for systemic administration to patients because of the short half-life of the molecule in the circulation (about 20 to 30 minutes after injection) and the severe side effects it produces when given at therapeutic doses.I5 Conversely, TNFa has remarkable antitumor/antileukemic effects even at much lower doses when continuously released. Such effects include the activation of phospholipase A, the intracellular production of hydroxyradicals, or the stimulation of secondary antitumor/antileukemic ~e l l s . '~~' ' Thus, there is a rationale for the application of low doses of TNFa that, ideally, should be released locally in the marrow where residual leukemia may reside. Furthermore, if immunotherapy is to have any adjunct antileukemia effect after BMT, it has to be administered early, before the malignancy would be likely to recur.
In an attempt to deliver TNFa to BM cells without doselimiting toxicity early after grafting, we have transduced murine hematopoietic progenitor cells with a retroviral vector containing the cDNA for TNFa. When transplanted into irradiated syngeneic recipients, temporary integration and expression of the TNFa gene in repopulating cells could be achieved. Because only local production of TNFa occurred, no systemic side effects were observed in these mice and marrow engraftment in the presence of TNFa production was not delayed. by reverse-transcription polymerase chain reaction (RT-PCR) using RNA isolated from the murine fibrosarcoma Fsa-N (Dougherty ST, et al; manuscript in preparation). To generate the retroviral vector JmTNFa , the cDNA for TNFa was first inserted into the Xhu I site of plasmid pTZI9Rtk-neo.IX A cassette containing both the TNFa gene and the Tk-promoted neomycin resistance gene was then isolated by Sma IiHindIll digestion and ligated into H p IfHindIII cut Jzen.1 (Fig l) ." The plasmid obtained was introduced into the ecotropic packaging line GP+E-86 by calcium-phosphate precipitation and transfected cells selected using the neomycin analog G4 I8 (0.5 mg/mL, active weight) (GIBCO-BRL, Grand
MATERIALS AND METHODS
Island, NY).2" Supernatants conditioned by the retroviral packaging line had active viral titers ranging between 2 X IO5 and 3 X 10" colony-forming units (CFUs)/mL when assayed for their ability to generate G418-resistant NIH3T3 cells. A control virus designated Jzen-neo was also constructed by inserting a 954-bp Mlu IIHincII fragment containing the coding region of the neoK gene from pMCIneo into the H p 1 site of Jzen. l ." Supernatants of this construct had active viral titers of greater than 1 X 10' CFU/mL.
Transduction ofmurine BM with the TNFa gene. BM cells were isolated from normal male Balbic mice (8 to I2 weeks old, Charles River, Montreal, Quebec, Canada) that had received 5-Fluorouracil (150 mg/kg body weight, interperitoneally) (Sigma Chemical CO, St Louis, MO) 4 days previously. Mice were kept in a standard animal facility and fed ad libitum in a nonprotective environment. BM was harvested by flushing the marrow cavities of the femurs and tibiae with a-minimal essential medium (aMEM) supplemented with 2 mmol/L glutamine, penicillin/streptomycin and 2% fetal calf serum (FCS; catalog no. SLM-4100; StemCell Technologies Inc, Vancow ver, BC, Canada). Marrow cells (2 to 4 X IO") without further separation were cocultured with the viral producer cell line (GP + E-86 cells) at 70% confluence in 100-mm tissue-culture dishes (catalog no. 3025; Falcon, Cockeysville, MD) in Dulbecco's moditied medium supplemented with 10% newborn calf serum, 2 mmol/L glutamine and penicillin/streptomycin (catalog no. SLM-2000; StemCell Technologies) and then irradiated with 1,500 cGy. To increase transfection efficiency, recombinant murine steel factor (I 00 ng/mL) (provided by Dr Widmer [Immunex Corp, Seattle, WA]), L 3 (20 ng/mL), IL-6 (15 ng/mL) (both cytokines provided by the Terry Fox Laboratory, Vancouver, BC), and 8 g/mL of polybrene were added to the cultures. After 36 hours of coculture, nonadherent cells were removed, washed twice with phosphate-buffered saline (PBS), and resuspended at I d cells 10.5 mL for transplantation into irradiated recipients.
Transduction efficiency in the nonadherent cells was determined after plating IO4 Jzen-neo or JmTNFa-infected viable cells in culture dishes (Greiner GmbH, Frickenhausen, Germany) containing Iscove's methylcellulose (catalog no. HCC-4100; StemCell Technologies) supplemented with 30% FCS, M2-mercaptoethanol and l mmol/L L-glutamine supplemented either with or without G418 (neomycin sulfate) (Geneticin, GIBCO-BRL) at 1.2 mg/mL (active weight). This concentration of G418 completely suppressed growth of nontransfected hematopoietic cells. Cultures were incubated at 37°C in 5% CO, for 12 to 14 days and colonies (>S0 cells) were Southern blot analysis. Genomic DNA was isolated from spleen colonies on days 7 and 12 and BM on days 7, 12, 40, and 90 after marrow injection by enzymatic digestion followed by phenol/ chloroform extraction and ethanol precipitation." Resuspended DNA was digested to completion with Xbu 1 to excise the entire 0.75-kb TNFa cDNA. The digested DNA was separated in a 1% agarose gel, and the fragments were transferred to a nylon membrane and hybridized to a "P-labeled TNFa cDNA probe. Filters were imaged by autoradiogl-aphy at -70°C using Kodak XAR-S film (Eastman-Kodak, Rochester, NY).
Norrhern /dol anul.y.sis. For documentation of gene expression, total RNA was isolated from spleen and marrow cells using the acid guanidinium-isothiocyanate phenol-chloroform single-step extraction method as described previously." Samples prepared from spleen cells on day I2 and marrow cells on days 12,40, and 90 were probed with the murine TNFa cDNA. A full-length murine &actin cDNA probe was used as a control. Probes were oligolaheled with
[12P] deoxycytidine triphosphate (dCTP), hybridized, and imaged by autoradiography as described above.
Determinalion of TNFa activily by LY2Y assuy. Bioactivity of TNFa in serum and supernatants of cultured marrow cells was dctermined based on the lysis of the transformed mouse fibroblast cell line L929 (American Type Culture Collection, Rockville, MD) as described p r e v i~u s l y .~~ Serum ( I mL) from mice that had received Jzen-neo or JmTNFa-transduced marrow was concentrated threefold using a Centricon I O Microconcentrator (Amicon, Beverly, MA). BM cells (IO") from the same mice were cultured in aMEM medium for 24 hours and the supernatant was also concentrated through a Centricon filter. For the L929 assay, target cells were incubated with the test samples in flat-bottom microtiter wells (Costar, Cambridge, MA). After 18 hours of incubation, L929 cells remaining intact were stained with crystal violet and dye uptake was measured using an ewyme-linked immunosorbent assay microplate reader (Microplate (Fig 2) . Data from day 7 were identical, but are not presented. The gene was also documented in BM cells on day 40 after transplantation, but was not found on day 90 (Fig 2) . These findings were correlated with the expression of the TNFa gene as documented by Northern blotting. TNFa mRNA was present in spleen cells on day 7 (result not shown) and day 12 (Fig 3) . Despite the presence of the gene on day 40 (documented by Southern blotting), no expression of the gene in spleen or marrow cells could be documented at that timepoint.
Bioactivity of TNFa in serum and marrow supernatant. To determine whether the expression of TNFa mRNA on day 12 resulted in production of bioactive TNFa production, 10' marrow cells obtained from the femur and tibia of the mice were cultured for 24 hours in medium and the bioactivity of TNFa in the supernatant measured using the L929 assay. Results were compared with those obtained with marrow cells obtained from mice that had received marrow transduced with the neoR gene ( Table l) . In addition, serum from recipients of transduced (neoK or TNFa) or nontransduced marrow was concentrated and TNFa measured. No bioactive TNFa could be detected in the serum of mice that were given the TNFa transduced marrow. In contrast, their marrow cells produced an amount of TNFa that was near that measured in the supernatant of the packaging cells and significantly higher than that found in control mice that had received Jzen-neo transduced marrow ( Table I) .
Engrqjiment of Jzen-neo-and JmTNFa-transduced marrow. Because TNFa is believed to be myelosuppressive, the cellularity of spleen (obtained on day 12 after BMT) and BM (obtained on day 12 and 40 after BMT) was determined by counting the number of nucleated cells from the spleen andor from all four limbs. Results suggest that the number of nucleated cells from the TNFa-transduced BM early after BMT (day 12) was slightly lower than that from the Jzen-neo-transduced or control mice ( Table 2) . However, the difference was not statistically significant. By day 40 after BMT, marrow cellularity had increased in all mice compared with day 12, and no differences were found between the different treatment groups.
DISCUSSION
Immunotherapy is increasingly being considered as a noncross-reactive treatment modality to prevent relapse, especially after autologous marrow transplantation, where no allogeneic GVL effect occurs. Because the function of cytotoxic cells recovers early after BMT, cytokines such as IL-2 and interferon a have been given to marrow recipients TNFa-transduced and control spleen cells.
pactin + -l
in an attempt to stimulate those cells toward antileukemic The rationale for the experiments presented here is based on the observation that the systemic administration of such cytokines can cause a number of side effects; it is also uncertain whether high enough concentrations are obtained locally in the marrow where residual leukemia is located.
TNFa has not been given after BMT because of its known short half-life and significant toxicities when given systemically.'' On the other hand, even low concentrations of this cytokine have a potent antitumor effect. To overcome the drawbacks of systemic application, we exploited the possibility of using TNFa gene transfer into hematopoietic progenitor cells as a means to deliver this antileukemic cytokine locally to the marrow.'6 Hematopoietic progenitor cells were 
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Abbreviation: ND, not detectable. *The bioactive concentration of TNFa was measured by L929 assay." The amount of TNFo (in pg) was determined in the supernatant of lo6 marrow cells cultured for 24 hours in a 10-cm2 flask in 10 mLaMEM medium. The supernatant was then concentrated threefold using a Centricon filter. TNFa was also measured in 1 mL mouse serum or supernatant of the packaging cell line, both of which were also concentrated through a Centricon filter. The mean t SE is presented for results obtained from three different mice. to have an antileukemic effect, either directly or through activation of secondary effector cells. The temporary expression of the TNFa gene confined to the time early after BMT may be desirable for the clinical situation, because immunotherapy should be delivered early after stem cell transplantation when only minimal disease is believed to be present. Hence, no attempt was made to achieve gene expression in early stem cells or devise strategies to maintain its expression. It is conceivable that gene integration and expression occurs only temporarily because of the lack of any selective pressure for maintaining this gene. Before proceeding to any clinical studies, it was important to document in a murine model that marrow recovery after BMT is not delayed, and TNFa , produced locally, does not induce unwanted effects (such as wasting with weight loss and fever) in recipients." These side effects seem to occur only at higher serum concentrations of TNFa that are not achieved with this approach. A marrow-suppressive effect has been reported in some~x.29 but not all studies." We have previously observed that TNFa has no negative effect on human long-term-culture initiating cells, which represent a cell population at the early stage of hematopoiesis (Gong and Klingemann, unpublished observation, February 1994). Hence, it was not unexpected to see maintained hematopoietic function in murine recipients of TNFa-transduced marrow.
Autologous hematopoietic progenitor cells could be useful vehicles for cytokine genes whose products can mediate antiFor personal use only. on August 30, 2017 . by guest www.bloodjournal.org From leukemic effects, but which would cause side effects if given systemically." In addition to being an adjunct treatment modality to arrest or eliminate residual disease after stem cell grafting for leukemia, this approach might also be useful for other malignant diseases in which minimal residual disease may persist after stem cell transplantation.
